December 2017 Slide of the Month

Methodology

New active substances (NASs) approved initially in 2012-2014 by either the European Medicines Agency (EMA) centralised procedure (N=7) or the United States Food and Drug Administration (FDA) (N=30) or both (N=81) were identified. The approval status was tracked for those NASs in Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissmedic and the Australian Therapeutic Goods Administration (TGA) until the end of 2016.

Key messages

  • Not all NASs approved in 2012-2014 by EMA, FDA or both received approval in the other 4 regulatory agencies (PMDA, Health Canada, Swissmedic and TGA) by the end of 2016.
  • There were more products only approved in FDA (30) as opposed to only EMA (7), but the biggest group of NASs were approved by both EMA and FDA (81).
  • For the 81 NASs approved by both EMA and FDA, 84% were approved by Swissmedic, followed by Health Canada (83%), TGA (80%) and PMDA (62%).
  • For the 30 NASs only approved by FDA, 27% were approved by Health Canada, followed by PMDA (23%), TGA (20%) and Swissmedic (10%).
  • For the 7 NASs only approved by EMA, 43% were approved by TGA, followed by PMDA (29%), Swissmedic (29%) and Health Canada (14%).
  • In general, NASs from a top companies (R&D budget> 3 billion USD in 2016) initially approved by EMA and FDA, had a higher proportion of approval in the other 4 agencies (~50-60%), compared with those approved by non-top companies (~20-30%).

Definitions

New active substance (NAS): A chemical, biological, biotechnology or radiopharmaceutical substance that has not been previously available for therapeutic use in humans and is destined to be made available as a ‘prescription only medicine’, to be used for the cure, alleviation, treatment, prevention or in vivo diagnosis of diseases in humans; Approval time: Time calculated from the date of submission to the date of approval by the agency (calendar days). This time includes agency and company time; Top company: Pharmaceutical company with R&D spending>3 billion USD in 2016 (http://www.pharmexec. com/2016-pharm -exec-50).

From: Bujar M, McAuslane N, Liberti L. 2017. R&D Briefing 65: New drug approvals in six major authorities 2007 – 2016: Focus on the internationalisation of medicines. Centre for Innovation in Regulatory Science. London, UK.

For more trends and analysis, please download the full CIRS R&D Briefing 65: http://www.cirsci.org/wp-content/uploads/2017/11/CIRS-RD-Briefing-65-20112017.pdf

DOWNLOAD THIS SLIDE HERE